Review article: The risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 8, 2001, Pages 1101-1108

  Aithal, G P ^a   Mansfield, J C ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE;

CANCER RISK; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENTERITIS; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LYMPHOMA; PRIORITY JOURNAL; PUBLICATION; QUANTITATIVE ASSAY; REVIEW;

6-MERCAPTOPURINE; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; EPIDEMIOLOGIC STUDIES; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LYMPHOMA; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034913946     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01023.x     Document Type: Review

References (54)

1. Chronic ulcerative colitis associated with malignant disease
2. Reticulum cell sarcoma: A case possibly originating in regional enteritis
3. Review article: The risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease
4. 6-mercaptopurine for the management of ulcerative colitis: A concept whose time has come
5. Antibodies to tumour necrosis factor α as treatment for Crohn's disease
6. The lymphomas
7. B cell lymphomas of mucosa associated lymphoma tissue (MALT)
8. Extranodal malignant lymphoma arising from mucosa associated lymphoid tissue
9. Incidence of cancer among patients with rheumatoid arthritis
10. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland
11. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study
12. Intestinal lymphoma associated with malabsorption
13. Primary intestinal Hodgkin's disease complicating ileal Crohn's disease
14. Celiac disease and malignancy
15. Primary malignant ymphoma of the large intestine complicating chronic inflammatory bowel disease
16. Primary intestinal lymphoma in Crohn's disease: Minute tumour with fatal outcome
17. The relationship between infliximab treatment and lymphoma in Crohn's disease
18. Lymphoma in inflammatory bowel disease
19. Lymphoma of the colon simulating ulcerative colitis: Report of four cases
20. Diffuse colonic mantle cell lymphoma in a patient with presumed ulcerative colitis
21. Primary T cell lymphoma of the colon
22. Primary ileo-cecal lymphoma mimicking Crohn's disease. Report of a case (Italian)
23. Pathological mimics of chronic inflammatory bowel disease
24. Malignancy in Crohn's disease
25. Cancer morbidity in ulcerative colitis
26. Extraintestinal cancers in inflammatory bowel disease
27. Extracolonic malignancies in inflammatory bowel disease
28. Diagnosis of extra-intestinal manifestations and cancers in IBD in large population-based databases
29. A potential increased risk of lymphatic and/or hematologic neoplasms among Crohn's disease and rheumatoid arthritis patients admitted to the University of Virginia Health Centre: A four year retrospective study
30. The incidence of non-Hodgkin's lymphoma in hospitalised Crohn's disease patients in Virginiaan administrative database study
31. Risk of lymphoma in inflammatory bowel disease
32. Increased association of lymphoma and inflammatory bowel disease
33. Increased risk of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunomosuppressive therapy but overall risk is low
34. Hodgkin's disease risk is increased in patients with ulcerative colitis
35. Are patients with inflammatory bowel disease (IBD) at increased risk for lymphoma?
36. Therapy of inflammatory bowel disease
37. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease
38. Risk of cancer in renal-transplant recipients
39. Collaborative United Kingdom-Australian study of cancer in patients treated with immunosuppressive drugs
40. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive therapy
41. 6-Mercaptopurine in the management of inflammatory bowel disease: Short and long-term toxicity
42. Diagnosis and treatment of transplant-related lymphoma
43. Crohn's disease lymph node homogenates produce murine lymphoma in athymic mice
44. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
45. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease
46. Long-term risk of malignancy after treatment of 1BD with azathioprine: A 30 year study
47. Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma
48. Intravenous cyclosporine for refractory attacks of Crohn's disease (CD): Long-term follow-up of patients
49. The mouse/human chimeric monoclonal antibody cA2 neutralises TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo
50. The turnout necrosis factor ligand and receptor families
51. Chronic exposure to tumour necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: Reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis
52. Long-term follow-up of patients treated with infliximab (anti-TNF antibody) in clinical trials
53. Review article: Safety of infliximab in clinical trials
54. Long-term safety follow-up of patients treated with infiiximab (anti TNFα antibody, remicade) in clinical trials